Potent antifibrillatory effect of combined blockade of calcium channels and 5-HT 2 receptors with nexopamil during myocardial ischemia and reperfusion in dogs: Comparison to diltiazem

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 6, 1996, Pages 777-787

  Nearing, Bruce D ^a,c,d   Hutter, Jon J ^b,d   Verrier, Richard L ^a,c,d,e  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c Deaconess Hospital   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Calcium channels; Diltiazem; Nexopamil; Reperfusion; Serotonin; T wave alternans

Indexed keywords

ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; NEXOPAMIL; SEROTONIN 2 RECEPTOR; SEROTONIN ANTAGONIST; UNCLASSIFIED DRUG;

ADRENERGIC STIMULATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOG; DRUG EFFECT; DRUG POTENCY; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HEMODYNAMICS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL; STELLATE GANGLION; SUBCUTANEOUS DRUG ADMINISTRATION; T WAVE;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM CHANNEL BLOCKERS; CORONARY CIRCULATION; DILTIAZEM; DOGS; ELECTROCARDIOGRAPHY; FEMALE; HEMODYNAMIC PROCESSES; MALE; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; SEROTONIN ANTAGONISTS; VERAPAMIL;

EID: 0029941377     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199606000-00003     Document Type: Article

References (53)

1. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-95.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
3. Waldo AL, Camm AJ, de Ruyter H, et al. Preliminary mortality results from the survival with oral D-sotalol (SWORD) trial [Abstract]. J Am Coll Cardiol 1995;00:15A.
4. Schwartz PJ, Vanoli E, Stramba-Badiale M, DeFerrari GM, Billman GE, Foreman RD. Autonomic mechanisms and sudden death. New insights from analysis of baroreceptor reflexes in conscious dogs with and without a myocardial infarction. Circulation 1988;78:969-79.
5. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med 1976;294:1165-70.
6. Verrier RL, Hagestad EL. Mechanisms involved in reperfusion arrhythmias. Eur Heart J 1986;7(suppl A):13-22.
7. Manning AS, Hearse DJ. Reperfusion-induced arrhythmias: mechanisms and prevention. J Mol Cell Cardiol 1984;16: 497-518.
8. Ridker PM, Manson JE, Buring JE, Muller JE, Hennekens CH. Circadian variation of acute myocardial infarction and the effect of low-dose aspirin in a randomized trial of physicians. Circulation 1990;82:897-902.
9. 2 receptor antagonist. Cardiovasc Drug Rev 1994;12:195-207.
10. 2+ and serotonin antagonist. J Cardiovasc Pharmacol 1994;23:922-31.
11. 2 receptor antagonist nexopamil (LU 49938) of intracoronary thrombus formation in a canine model of arterial stenosis and intimai damage. J Cardiovasc Pharmacol 1993;22:687-94.
12. Nearing BD, Huang AH, Verrier RL. Dynamic tracking of cardiac vulnerability by complex demodulation of the T wave. Science 1991;252:437-40.
13. Nearing BD, Oesterle SN, Verrier RL. Quantification of ischaemia-induced vulnerability by precordial T-wave alternans analysis in dog and human. Cardiovasc Res 1994;28: 1440-9.
14. Verrier RL, Nearing BD. Electrophysiologic basis for T-wave alternans as an index of vulnerability to ventricular fibrillation. J Cardiovasc Electrophysiol 1994;5:445-61.
15. Rosenbaum DS, Jackson LE, Smith JM, Garan H, Ruskin JN, Cohen RJ. Electrical alternans and vulnerability to ventricular arrhythmia. N Engl J Med 1994;330:235-41.
16. Russell DC, Smith JH, Oliver MF. Transmembrane potential changes and ventricular fibrillation during repetitive myocardial ischaemia in the dog. Br Heart J 1979;42:88-96.
17. Clusin WT, Bristow MR, Baim DS, et al. The effects of diltiazem and reduced serum ionized calcium on ischemic ventricular fibrillation in the dog. Circ Res 1982;50:518-26.
18. Zaza A, Malfatto G, Rosen MR. Electrophysiologic effects of ketanserin on canine Purkinje fibers, ventricular myocardium and the intact heart. J Pharmacol Exp Ther 1989;250: 397-405.
19. El-Mahdy SAM. 5-hydroxytryptamine (serotonin) enhances ventricular arrhythmias induced by acute coronary artery ligation in rats. Res Commun Chem Pathol Pharmacol 1990; 68:383-6.
20. Coker SJ, Dean HG, Kane KA, Parratt JR. The effects of ICS 205-930, a 5-HT antagonist, on arrhythmias and catecholamine release during canine myocardial ischaemia and reperfusion. Eur J Pharmacol 1986;127:211-8.
21. Saxena PR, Villalón CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol 1990;15 (suppl 7):S17-34.
22. Lamping KG, Marcus ML, Dole WP. Removal of the endothelium potentiates canine large coronary artery constrictor responses to 5-hydroxytryptamine in vivo. Circ Res 1985; 57:46-54.
23. Kim YD, Fomsgaard JS, Heim KF, et al. Brief ischemia-reperfusion induces stunning of endothelium in canine coronary artery. Circulation 1992;85:1473-82.
24. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary arteriosclerosis and control patients. N Engl J Med 1991;324:641-8.
25. Levy MN. Role of calcium in arrhythmogenesis. Circulation 1989;80(suppl IV):IV-23-30.
26. Billman GE. Effect of calcium channel antagonists on susceptibility to sudden cardiac death: protection from ventricular fibrillation. J Pharmacol Exp Ther 1989;248:1334-42.
27. Hashimoto H, Suzuki K, Miyake S, Nakashima M. Effects of calcium antagonists on the electrical alternans of the ST segment and on associated mechanical alternans during acute coronary occlusion in dogs. Circulation 1983;68: 667-72.
28. Schwartz PJ, Priori SG, Vanoli E, Zaza A, Zuanetti G. Efficacy of diltiazem in two experimental feline models of sudden cardiac death. J Am Coll Cardiol 1986;8:661-8.
29. Uprichard ACG, Lucchesi BR. The efficacy of antiarrhythmic drugs as antifibrillatory agents. In: Singh BN, Wellens HJJ, Hiraoka M, eds. Electropharmacological control of cardiac arrhythmias: to delay conduction or to prolong refractoriness? Mt. Kisco, NY: Futura, 1994:291-312.
30. Schwartz PJ, Vanoli E, Zaza A, Zuanetti G. The effect of antiarrhythmic drugs on life-threatening arrhythmias induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity. Am Heart J 1985;109: 937-48.
31. Hayakawa T, Nagamoto Y, Ninomiya K, Abe S, Fukumoto T, Kuroiwa A. Effects of heart rate and diltiazem hydrochloride on alternans of ST segment elevation and ventricular arrhythmia during acute myocardial ischaemia in dogs. Cardiovasc Res 1989;23:520-8.
32. The Israeli SPRINT Study Group. Secondary prevention reinfarction Israeli nifedipine trial (SPRINT). A randomized intervention trial of nifedipine in patients with acute myocardial infarction. Eur Heart J 1988;9:354-64.
33. SPRINT study group. The secondary prevention reinfarction Israeli nifedipine trial (SPRINT) II: design and methods, results. Eur Heart J 1988;9(suppl 1):350A.
34. Priori SG, Zuanetti G, Schwartz PJ. Ventricular fibrillation induced by the interaction between acute myocardial ischemia and sympathetic hyperactivity: effect of nifedipine. Am Heart J 1988;116:37-43.
35. Task force of the working group on arrhythmias of the European Society of Cardiology. The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Circulation 1991;84:1831-51.
36. Brooks WW, Verrier RL, Lown B. Protective effect of verapamil on vulnerability to ventricular fibrillation during myocardial ischaemia and reperfusion. Cardiovasc Res 1980;14:295-302.
37. Surawicz B. Ventricular fibrillation. J Am Coll Cardiol 1985; 5:43B-54B.
38. Janse MJ, Wit AL. Electrophysiological mechanisms of ventricular arrhythmias resulting from myocardial ischemia and infarction. Physiol Rev 1989;69:1049-169.
39. Brooks WW, Conrad CH, Morgan JP. Reperfusion induced arrhythmias following ischaemia in intact rat heart: role of intracellular calcium. Cardiovasc Res 1995;29:536-42.
40. Thandroyen FT, Morris AC, Hagler HK, et al. Intracellular calcium transients and arrhythmia in isolated heart cells. Circ Res 1991;69:810-9.
41. Thandroyen FT, McCarthy J, Burton KP, Opie LH. Ryanodine and caffeine prevent ventricular arrhythmias during acute myocardial ischemia and reperfusion in rat heart. Circ Res 1988;62:306-14.
42. Vanoli E, Priori SG, Nakagawa H, et al. Sympathetic activation, ventricular repolarization and Ikr blockade: implications for the antifibrillatory efficacy of potassium channel blocking agents. J Am Coll Cardiol 1995;25:1609-14.
43. O'Rourke B, Ramza BM, Marban E. Oscillations of membrane current and excitability driven by metabolic oscillations in heart cells. Science 1994;265:962-6.
44. Lee H-C, Mohabir R, Smith N, Franz MR, Clusin WT. Effect of ischemia on calcium-dependent fluorescence transients in rabbit hearts containing Indo 1. Correlation with monophasic action potentials and contraction. Circulation 1988;78:1047-59.
45. Saitoh H, Bailey JC, Surawicz B. Action potential duration alternans in dog Purkinje and ventricular muscle fibers: further evidence in support of two different mechanisms. Circulation 1989;80:1421-31.
46. Coker SJ, Parratt JR, Ledingham I McA, Zeitlin IJ. Thromboxane and prostacyclin release from ischaemic myocardium in relation to arrhythmias. Nature 1981;291:323-4.
47. Coker SJ, Parratt JR, Ledingham I McA, Zeitlin IJ. Evidence that thromboxane contributes to ventricular fibrillation induced by reperfusion of the ischaemic myocardium. J Mol Cell Cardiol 1982;14:483-5.
48. Folts JD, Gallagher K, Rowe GG. Blood flow reduction in stenosed canine coronary arteries: vasospasm or platelet aggregation? Circulation 1982;65:248-55.
49. Kowey PR, Verrier RL, Lown B, Handin RI. Influence of intracoronary platelet aggregation on ventricular electrical properties during partial coronary stenosis. Am J Cardiol 1983;51:596-602.
50. Bush LR, Campbell WB, Tilton GD, Buja LM, Willerson JT. Effects of the selective thromboxane synthesis inhibitor dazoxiben on variations in cyclic blood flow in stenosed canine coronary arteries. Circulation 1984;69:1161-70.
51. Danish Study Group on Verapamil in Myocardial Infarction. Effect of verapamil on mortality and major events after acute myocardial infarction (The Danish Verapamil Infarction Trial II - DAVIT II). Am J Cardiol 1990;66:779-85.
52. Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med 1988;319:385-92.
53. Salerno JA, Previtali M, Panciroli C, et al. Ventricular arrhythmias during acute myocardial ischaemia in man. The role and significance of R-ST-T alternans and the prevention of ischaemic sudden death by medical treatment. Eur Heart J 1986;7:63-75.